DMRA

Damora Therapeutics Inc

A clinical-stage biotech developing antibody drugs that target a mutated protein called calreticulin, which drives the blood disorders essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, was born at Paragon Therapeutics, a firm that launches drug companies from its own research — Damora was the sixth spun out. The company itself was once named Galecto and adopted the Damora name after acquiring the private firm behind DMR-001 in late 2025.